A Novel and Selective Poly (ADP-Ribose) Polymerase Inhibitor Ameliorates Chemotherapy-Induced Painful Neuropathy

@inproceedings{Ta2013ANA,
  title={A Novel and Selective Poly (ADP-Ribose) Polymerase Inhibitor Ameliorates Chemotherapy-Induced Painful Neuropathy},
  author={Lauren E. Ta and James D. Schmelzer and Allan J. Bieber and Charles L Loprinzi and Gary C. Sieck and Jill D. Brederson and Philip A. Low and Anthony J Windebank},
  booktitle={PloS one},
  year={2013}
}
BACKGROUND Chemotherapy-induced neuropathy is the principle dose limiting factor requiring discontinuation of many chemotherapeutic agents, including cisplatin and oxaliplatin. About 30 to 40% of patients receiving chemotherapy develop pain and sensory changes. Given that poly (ADP-ribose) polymerase (PARP) inhibition has been shown to provide neuroprotection, the current study was developed to test whether the novel PARP inhibitor compound 4a (analog of ABT-888) would attenuate pain in… CONTINUE READING